JY
APRE icon

Jeff Yass’s Aprea Therapeutics APRE Stock Holding History

Jeff Yass’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-510
Closed -$19K – 12814
2022
Q1 		$19K Sell
510
-1,200
-70% -$49.2K ﹤0.01% 12632
2021
Q4 		$98K Sell
1,710
-4,965
-74% -$439K ﹤0.01% 12166
2021
Q3 		$682K Buy
6,675
+3,115
+88% +$283K ﹤0.01% 8592
2021
Q2 		$347K Buy
3,560
+2,555
+254% +$236K ﹤0.01% 10455
2021
Q1 		$103K Buy
+1,005
New +$117K ﹤0.01% 11847

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jeff Yass's APRE Position: Q2 2026 in Review

Jeff Yass increased its Aprea Therapeutics (APRE) stake by 168% in Q2 2026, buying an estimated $18.3K and bringing the position to 34,939 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #12981.

Jeff Yass first reported a position in APRE in Q2 2021 and has held it in 10 quarters since. The position peaked at $1.02M in Q3 2021. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • Jeff Yass held 34,939 shares of Aprea Therapeutics worth $28K as of Q2 2026.
  • Jeff Yass bought 21,921 Aprea Therapeutics shares in Q2 2026, an estimated $18.3K.
  • Aprea Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12981 holding.
  • Jeff Yass first reported a position in Aprea Therapeutics in Q2 2021 and has held it in 10 quarters since.
  • Jeff Yass's Aprea Therapeutics position peaked at $1.02M in Q3 2021.
  • 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.